Literature DB >> 26338995

Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6.

Hongcheng Sun1, Huamei Tang2, Dacheng Xie3, Zhiliang Jia4, Zhenyu Ma5, Daoyan Wei4, Lopa Mishra4, Yong Gao3, Shaojiang Zheng6, Keping Xie7, Zhihai Peng8.   

Abstract

PURPOSE: Tumor differentiation is a behavioral index for hepatocellular carcinoma (HCC) and a prognostic factor for patients with HCC who undergo orthotopic liver transplantation (OLT). However, the molecular basis for HCC differentiation and prognostic value of the underlying molecules that regulate HCC differentiation are unclear. In this study, we defined a potential driver pathway for HCC differentiation and prognostication. EXPERIMENTAL
DESIGN: The regulation and function of Krüppel-like factor 4 (KLF4) and hepatocyte nuclear factor-6 (HNF-6) in HCC differentiation was evaluated using human tissues, molecular and cell biology, and animal models, and its prognostic significance was determined according to its impact on patient survival.
RESULTS: There was a direct relationship between the expression levels of KLF4 and HNF6 in HCC. Reduced KLF4 or HNF6 expression correlated with high HCC grade. Poorly differentiated HCC cells had lower expression of KLF4 or HNF6 and differentiation-associated markers than did well-differentiated cells. Elevated KLF4 of HNF6 expression induced differentiation of poorly differentiated hepatoma cells. Mechanistically, KLF4 trans-activated HNF-6 expression. Restored HNF-6 expression upregulated expression of differentiation-associated markers and inhibited HCC cell migration and invasion, whereas HNF-6 knockdown did the opposite. Loss of KLF4 expression in primary HCC correlated with reduced overall survival and shortened relapse-free survival durations after OLT. Combination of KLF4 expression and the Milan criteria improved prognostication for HCC after OLT.
CONCLUSIONS: The dysregulated KLF4/HNF-6 pathway drives dedifferentition and progression of HCC, and KLF4 is a biomarker for accurate prognostication of patients with HCC treated by OLT when integrated with the Milan Criteria. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26338995      PMCID: PMC4715982          DOI: 10.1158/1078-0432.CCR-15-0528

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  49 in total

1.  Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time?

Authors:  Francis Y Yao; John P Roberts
Journal:  Liver Transpl       Date:  2004-07       Impact factor: 5.799

2.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

3.  The structure of the Klf4 DNA-binding domain links to self-renewal and macrophage differentiation.

Authors:  Anja Schuetz; Didier Nana; Charlotte Rose; Georg Zocher; Maja Milanovic; Jessica Koenigsmann; Rosel Blasig; Udo Heinemann; Dirk Carstanjen
Journal:  Cell Mol Life Sci       Date:  2011-02-03       Impact factor: 9.261

Review 4.  Krüppel-like factors in hepatocellular carcinoma.

Authors:  Xiao-Jie Lu; Yan Shi; Jin-Lian Chen; Shijie Ma
Journal:  Tumour Biol       Date:  2015-02-06

5.  Increased expression of hepatocyte nuclear factor 6 stimulates hepatocyte proliferation during mouse liver regeneration.

Authors:  Yongjun Tan; Yuichi Yoshida; Douglas E Hughes; Robert H Costa
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

6.  Expression of HNFs and C/EBP alpha is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and immortalized hepatocytes.

Authors:  Tadashi Ishiyama; Junko Kano; Yuko Minami; Tatsuo Iijima; Yukio Morishita; Masayuki Noguchi
Journal:  Cancer Sci       Date:  2003-09       Impact factor: 6.716

Review 7.  Strategies for the management of hepatocellular carcinoma.

Authors:  Myron Schwartz; Sasan Roayaie; Manousos Konstadoulakis
Journal:  Nat Clin Pract Oncol       Date:  2007-07

8.  Nuclear Krüppel-like factor 4 expression is associated with human skin squamous cell carcinoma progression and metastasis.

Authors:  Yi-Ju Chen; Chun-Ying Wu; Chia-Che Chang; Chieh-Ju Ma; Mu-Chun Li; Chuan-Mu Chen
Journal:  Cancer Biol Ther       Date:  2008-05-20       Impact factor: 4.742

9.  Krüppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression.

Authors:  Ze-Shiang Lin; Hsiao-Chien Chu; Yi-Chen Yen; Brian C Lewis; Ya-Wen Chen
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

10.  Inhibition of the liver enriched protein FOXA2 recovers HNF6 activity in human colon carcinoma and liver hepatoma cells.

Authors:  Frank Lehner; Ulf Kulik; Juergen Klempnauer; Juergen Borlak
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

View more
  13 in total

Review 1.  SP and KLF Transcription Factors in Digestive Physiology and Diseases.

Authors:  Chang-Kyung Kim; Ping He; Agnieszka B Bialkowska; Vincent W Yang
Journal:  Gastroenterology       Date:  2017-03-30       Impact factor: 22.682

2.  Krüppel-like Factor 4 Suppresses Serine/Threonine Kinase 33 Activation and Metastasis of Gastric Cancer through Reversing Epithelial-Mesenchymal Transition.

Authors:  Fanyang Kong; Tao Sun; Xiangyu Kong; Dacheng Xie; Zhaoshen Li; Keping Xie
Journal:  Clin Cancer Res       Date:  2018-01-24       Impact factor: 12.531

Review 3.  Aberrant lipid metabolism as a therapeutic target in liver cancer.

Authors:  Evans D Pope; Erinmarie O Kimbrough; Lalitha Padmanabha Vemireddy; Phani Keerthi Surapaneni; John A Copland; Kabir Mody
Journal:  Expert Opin Ther Targets       Date:  2019-05-10       Impact factor: 6.902

4.  RYBP Expression Is Regulated by KLF4 and Sp1 and Is Related to Hepatocellular Carcinoma Prognosis.

Authors:  Qiaojiajie Zhao; Weihua Cai; Xuan Zhang; Shuo Tian; Junwen Zhang; Haibo Li; Congcong Hou; Xiaoli Ma; Hong Chen; Bingren Huang; Deng Chen
Journal:  J Biol Chem       Date:  2016-12-27       Impact factor: 5.157

Review 5.  The Prognostic Value of Decreased KLF4 in Digestive System Cancers: A Meta-Analysis from 17 Studies.

Authors:  Jianpei Hu; Huipu Li; Chunyu Wu; Xueying Zhao; Chaodong Liu
Journal:  Dis Markers       Date:  2017-09-14       Impact factor: 3.434

Review 6.  Tuning up Transcription Factors for Therapy.

Authors:  Attila Becskei
Journal:  Molecules       Date:  2020-04-20       Impact factor: 4.411

7.  KLF4-Mediated CDH3 Upregulation Suppresses Human Hepatoma Cell Growth and Migration via GSK-3β Signaling.

Authors:  Li Li; Shijun Yu; Qiong Wu; Ning Dou; Yandong Li; Yong Gao
Journal:  Int J Biol Sci       Date:  2019-03-10       Impact factor: 6.580

8.  Differentiation-inducing therapeutic effect of Notch inhibition in reversing malignant transformation of liver normal stem cells via MET.

Authors:  Hao Luo; Wei-Hui Liu; Hong-Yin Liang; Hong-Tao Yan; Ning Lin; Dong-Yu Li; Tao Wang; Li-Jun Tang
Journal:  Oncotarget       Date:  2018-02-05

9.  Mechano-signalling, induced by fullerene C60 nanofilms, arrests the cell cycle in the G2/M phase and decreases proliferation of liver cancer cells.

Authors:  Malwina Sosnowska; Marta Kutwin; Sławomir Jaworski; Barbara Strojny; Mateusz Wierzbicki; Jarosław Szczepaniak; Maciej Łojkowski; Wojciech Święszkowski; Jaśmina Bałaban; André Chwalibog; Ewa Sawosz
Journal:  Int J Nanomedicine       Date:  2019-08-06

10.  USP11 degrades KLF4 via its deubiquitinase activity in liver diseases.

Authors:  Heeyoung Yang; Daeui Park; Jeongho Ryu; Tamina Park
Journal:  J Cell Mol Med       Date:  2021-06-10       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.